Business Context and Reporting Period
Company: McKesson Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended September 30, 2003 (Fiscal Year 2004)
Business Overview: McKesson operates through three primary segments: Pharmaceutical Solutions, Medical-Surgical Solutions, and Information Solutions. The company is a leading distributor of pharmaceuticals and medical products and a provider of information technology solutions for healthcare.
Key Financial Metrics
| Metric (in millions) | Q2 2003 | Q2 2002 | 6 Months 2003 | 6 Months 2002 |
|---|---|---|---|---|
| Revenues | $16,810.1 | $13,690.3 | $33,334.3 | $27,313.5 |
| Gross Profit | $811.7 | $739.3 | $1,598.2 | $1,490.1 |
| Operating Income | $226.4 | $220.0 | $477.2 | $424.5 |
| Net Income | $156.5 | $124.8 | $312.1 | $242.1 |
| Diluted EPS | $0.53 | $0.42 | $1.05 | $0.82 |
| Cash & Equivalents (End of Period) | $261.6 | $300.3 | $261.6 | $300.3 |
| Working Capital | $3,647.2 | N/A | $3,647.2 | N/A |
| Debt to Capital Ratio | 22.1% | N/A | 22.1% | N/A |
Note: Cash flow from operating activities for the six months ended Sept 30, 2003, was a net use of $288.4 million, compared to a net use of $25.5 million in the prior year period.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 23% in the quarter and 22% year-to-date, driven primarily by the Pharmaceutical Solutions segment (94% of total revenue). Growth was fueled by market expansion, increased institutional pharmacy distribution, and a 48% increase in sales to customers' warehouses.
- Profitability: Net income rose 25% in the quarter and 29% year-to-date. Diluted EPS increased 26% and 28% respectively.
- Margin Compression: Consolidated gross profit margin decreased 57 basis points in the quarter and 67 basis points year-to-date. This was primarily due to the higher proportion of lower-margin Pharmaceutical Solutions revenue and a decline in U.S. pharmaceutical distribution margins, partially offset by improvements in Medical-Surgical and Information Solutions.
- Segment Performance:
- Pharmaceutical Solutions: Operating profit decreased 3% in the quarter but increased 6% year-to-date.
- Medical-Surgical Solutions: Operating profit increased 70% in the quarter and 40% year-to-date due to restructuring benefits and gross profit improvements.
- Information Solutions: Operating profit increased 71% in the quarter and 46% year-to-date, aided by a reversal of customer settlement reserves.
Guidance, Outlook, Risks, and Unusual Items
Unusual Items and One-Time Adjustments
- Bad Debt Provision: A $30.0 million charge was recorded in the Pharmaceutical Solutions segment due to a customer bankruptcy.
- Tax Benefit: A $15.3 million income tax benefit was recognized from favorable settlements with the IRS regarding amended returns for 1997 and 1998.
- Restructuring & Severance: $9.8 million in severance charges were recorded, primarily in the Information Solutions International business. Net restructuring charges for the six months were $1.8 million.
- Reserve Reversals: A $19.7 million credit was recorded for the reversal of customer settlement reserves in the Information Solutions segment.
Outlook and Management Commentary
- Medical-Surgical Restructuring: The segment anticipates initiating a restructuring program in the third quarter of 2004 to reduce expenses following the loss of a significant acute care customer.
- Revenue Recognition Change: The Automation business within Pharmaceutical Solutions will defer revenue recognition until customer installation for new contracts entered into on or after October 1, 2003, due to increased complexity in integrated solutions.
- Capital Allocation: The Board approved a new $250 million stock repurchase program on October 30, 2003. The company repurchased $75.3 million of stock during the six-month period.
Risks and Contingencies
- Litigation: Ongoing securities litigation regarding the 1999 accounting restatement at HBO & Company (now McKesson Information Solutions). The company states it is not feasible to predict the outcome or potential loss range.
- Government Investigation: The U.S. Attorney's Office is investigating the marketing and Medicare reimbursement of enteral nutritional products. Two employees have been indicted; the company remains a subject of the investigation.
- Customer Concentration: Risks associated with substantial defaults by large customers or the loss of major supplier relationships.
Investor Verification Checklist
- Customer Bankruptcy Impact: Verify the long-term implications of the $30 million bad debt provision and the potential for further credit losses in the Pharmaceutical segment.
- Medical-Surgical Restructuring: Monitor the execution and cost of the planned Q3 2004 restructuring program following the loss of a major acute care customer.
- Litigation Exposure: Track developments in the HBO & Company securities litigation and the government investigation into enteral nutritional products for potential material liabilities.
- Margin Trends: Assess whether the decline in Pharmaceutical Solutions gross margins is a temporary anomaly or a structural shift due to generic drug pricing and warehouse sales mix.
- Working Capital Requirements: Review the significant increase in inventory and receivables ($900 million cash outflow for inventory in six months) and its impact on future operating cash flows.